|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM125298234 |
| 003 |
DE-627 |
| 005 |
20231222205420.0 |
| 007 |
tu |
| 008 |
231222s2003 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0418.xml
|
| 035 |
|
|
|a (DE-627)NLM125298234
|
| 035 |
|
|
|a (NLM)12763477
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Porpiglia, Andrea S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reconstitution of B cell function in murine models of immunodeficiency
|
| 264 |
|
1 |
|c 2003
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.07.2003
|
| 500 |
|
|
|a Date Revised 07.11.2019
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Murine models of immunodeficiency were used to evaluate strategies that might allow B cell engraftment in patients with X-linked agammaglobulinemia. Mice with defects in Btk or mu heavy chain were given 2.5 x 10(6) bone marrow cells from wild-type congenic donors. In the absence of any preparative regimen or immunosuppression, Btk-deficient mice on the CBA background developed normal concentrations of serum IgM and IgG3 by 12 weeks posttransplant. By contrast, mu heavy chain-deficient mice on the C57BL/6 background required some immunosuppression to achieve engraftment. Treatment of these mice with anti-T-cell antibodies 2 and 4 days prior to transplant resulted in normal concentrations of serum immunoglobulins by 6 weeks posttransplant. These pretreated mice had only 10% of the normal number of splenic B cells and they had no evidence of donor T cell engraftment. These results suggest that myelotoxic drugs may not be needed to achieve B cell engraftment in B-cell-deficient subjects
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, U.S. Gov't, P.H.S.
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin mu-Chains
|2 NLM
|
| 650 |
|
7 |
|a Ficoll
|2 NLM
|
| 650 |
|
7 |
|a 25702-74-3
|2 NLM
|
| 650 |
|
7 |
|a DNA
|2 NLM
|
| 650 |
|
7 |
|a 9007-49-2
|2 NLM
|
| 650 |
|
7 |
|a Protein-Tyrosine Kinases
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 650 |
|
7 |
|a Agammaglobulinaemia Tyrosine Kinase
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.2
|2 NLM
|
| 700 |
1 |
|
|a Rohrer, Jurg
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Conley, Mary Ellen
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 107(2003), 2 vom: 30. Mai, Seite 90-7
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:107
|g year:2003
|g number:2
|g day:30
|g month:05
|g pages:90-7
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 107
|j 2003
|e 2
|b 30
|c 05
|h 90-7
|